Table 2. Numbers of major CVD events during the follow-up.
| Total | Male sex | Female sex | ||||
|---|---|---|---|---|---|---|
| Normouricemia (n = 1749) | Hyperuricemia (n = 393) | Normouricemia (n = 954) | Hyperuricemia (n = 238) | Normouricemia (n = 795) | Hyperuricemia (n = 155) | |
| At 1-year | ||||||
| CAD | 15 | 5 | 10 | 3 | 5 | 2 |
| Congestive heart failure | 4 | 2 | 2 | 1 | 2 | 1 |
| Stroke | 6 | 2 | 3 | 1 | 3 | 1 |
| Peripheral vascular disease | 0 | 1 | 0 | 0 | 0 | 1 |
| At 2-year | ||||||
| CAD | 25 | 8 | 16 | 5 | 9 | 3 |
| Congestive heart failure | 6 | 3 | 3 | 2 | 3 | 1 |
| Stroke | 11 | 2 | 6 | 1 | 5 | 1 |
| Peripheral vascular disease | 2 | 2 | 1 | 1 | 1 | 1 |
| At 3-year | ||||||
| CAD | 31 | 13 | 18 | 8 | 13 | 5 |
| Congestive heart failure | 15 | 5 | 9 | 3 | 6 | 2 |
| Stroke | 13 | 6 | 8 | 4 | 5 | 2 |
| peripheral vascular disease | 8 | 3 | 5 | 2 | 3 | 1 |
| At 4-year | ||||||
| CAD | 39 | 16 | 22 | 9 | 17 | 6 |
| Congestive heart failure | 16 | 6 | 10 | 4 | 6 | 2 |
| Stroke | 18 | 9 | 11 | 6 | 7 | 3 |
| Peripheral vascular disease | 11 | 5 | 7 | 4 | 4 | 1 |
| At 5-year | ||||||
| CAD | 44 | 17 | 26 | 11 | 18 | 7 |
| Congestive heart failure | 21 | 7 | 13 | 5 | 8 | 2 |
| Stroke | 23 | 13 | 13 | 8 | 10 | 5 |
| Peripheral vascular disease | 12 | 6 | 7 | 4 | 5 | 2 |
| Cumulative Numbers of major CVD events over 5 years | ||||||
| CAD | 154 (8.8%) | 59 (15.0%) | 92 (9.7 %) | 36 (15.1%) | 62 (7.8%) | 23 (14.8%) |
| Congestive heart failure | 62 (3.6%) | 23 (5.9%) | 37 (3.9%) | 15 (6.1%) | 25 (3.2%) | 8 (5.2%) |
| Stroke | 73 (4.2%) | 32 (8.1%) | 41 (4.3%) | 20 (8.2%) | 30 (3.8%) | 12 (7.7%) |
| Peripheral vascular disease | 33 (1.9%) | 17 (4.6%) | 20 (2.1%) | 11 (4.6%) | 13 (1.6%) | 6 (3.7%) |
CAD = coronary artery disease; CVD = cardiovascular disease.